Finiac
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and F...
RISK EFFICIENCY
0.87
Biogen Inc's risk efficiency is 0.87, which is OK. By comparison, the S&P500 is -0.39.
Increasing quickly over the past 4 weeks.
View full risk analysis for Biogen Inc
DSCORE
3.14%
Biogen Inc's dScore is 3.14% , which is more volatile than the S&P500 (2.79%).
View full volatility analysis for Biogen Inc
GROWTH
28.82%
Biogen Inc has grown by 28.82% over the past year. By comparison, the S&P500 has lost -7.38%.
View full growth analysis for Biogen Inc
ValueStockGeek
8 Assets